RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:QuestionIt seems like that, 1 to 2.5% royalty payment of net sales is vey low cost also PDC's are cheap to manufacture so the profit margins are going to be very good if they sublicense the drug the royalties are in low single digits with their worldwide patent coverage one or more deals in different jurisdictions will add nice added revenues. If their technology proven to be successful in treatment of various cancers they should consider those options to maximize the revenues.
SPCEO1 wrote: Do I understand it correctly that if TH keeps the rights to market TH-1902 themselves they pay significantly less royalties than if the license others to market it? Still, while that incentivizes TH to hold onto as many indications as possible, they almost certainly would still partner on many indications as they likely don't have the capacity to gear up to market all the potential indications (assuming the drug works as we expect).
qwerty22 wrote: Transfert are named as owner of Katana in the sale contract. If I had to guess then some sort of entity set up to handle the royalty payments on behalf of the actual owners. No matter.
As consultants, employees, shareholders and royalty receivers they are invested in the future of the program in the short, medium and long term. They haven't taken the loot and left the scene.
palinc2000 wrote: Royalty to whom?
scarlet1967 wrote: Yep, but it will be quite low and based on NET sales unless they sublicense the drug.
qwerty22 wrote: So there is a royalty?
scarlet1967 wrote: "The royalties payable under the Transfert Plus License Agreement vary between 1% and 2.5% on net sales of a product based on the licensed technology. If we enter into a sublicense agreement, we must pay amounts varying between 5% and 15% of the revenues received under such sublicense agreement. The percentage varies based on the timing of the execution of such sublicense agreement."